Synthes guilty in S&N (Smith & Nephew) patent case:
This article was originally published in Clinica
Smith & Nephew (S&N) has won a patent infringement dispute concerning two intramedullary nail products sold by rival Synthes. A US district court ruled that Synthes' trochanteric fixation nail and proximal femoral nail products did infringe two patents owned by S&N, and upheld the validity of these patents. Remedies for this infringement have yet to be determined by the court. Intramedullary nails are placed inside the bone to help healing of bone fractures.
You may also be interested in...
Orladeyo is the first oral prophylactic approved in the US for hereditary angioedema, with Japan and EU approvals expected to follow. Pricing of $485,000 a year undercuts segment leader.
Results of Study to Assess Statin Residual Risk with Epanova in High Cardiovascular Risk Patients with Hypertriglyceridemia “should prompt reconsideration of [OTC] mixed omega-3 fatty acid products for [atherosclerotic cardiovascular disease] prevention,” say cardiologists in an editorial published with JAMA study.
In a final guidance from the US agency, regulators say most combination product questions are best resolved through traditional pathways and noted that initiating a so-called combination product agreement meeting may be unproductive.